Gut microbes promote chemoradiotherapy resistance via metabolic cross-feeding

Gut microorganisms can modulate response to cancer therapies. In this issue of Cancer Cell, Teng et al. trace the gut bacteria and metabolites in rectal cancer patients over the course of neoadjuvant chemoradiotherapy and identify Bacteroides vulgatus as a driver bacterium of therapeutic resistance by supplying tumors with nucleotides. Gut microorganisms can modulate response to cancer therapies. In this issue of Cancer Cell, Teng et al. trace the gut bacteria and metabolites in rectal cancer patients over the course of neoadjuvant chemoradiotherapy and identify Bacteroides vulgatus as a driver bacterium of therapeutic resistance by supplying tumors with nucleotides. Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancerTeng et al.Cancer CellDecember 22, 2022In BriefTeng et al. report that Bacteroides vulgatus-mediated nucleotide biosynthesis attenuates the response of rectal cancer patients to chemoradiotherapy; uric acid is a potential prognosis marker for rectal cancer patients receiving chemoradiotherapy. The findings give insights into the cross-talk between cancer cells and gut microbiota during cancer therapies. Full-Text PDF Open Access